ArticleWorld journal of hepatology2010
Hepatocellular carcinoma in thalassemia: A critical review.
Article in World journal of hepatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- Evaluation of Five Plasma miRNAs as Biomarkers for Minimally Invasive Staging of Liver Fibrosis in β-Thalassaemia Patients.International journal of molecular sciences · 2025Article
- Isolated focal intrahepatic extramedullary hematopoiesis mimicking hepatocellular carcinoma in a cirrhotic patient with secondary hemochromatosis from thalassemia.Gastroenterology and hepatology from bed to bench · 2023Article
- Current status of beta-thalassemia and its treatment strategies.Molecular genetics & genomic medicine · 2021Review
- Evidence-based medicine and Management of Hepatocellular Carcinoma in Thalassemia.BMC gastroenterology · 2020Article
- Article
- Increased Bone MarrowMolecular imaging and radionuclide therapy · 2020Article
- Characteristics and Prognosis of Hepatocellular Carcinoma in Multi-Transfused Patients with β-Thalassemia. Experience of a Single Tertiary Center.Mediterranean journal of hematology and infectious diseases · 2020Article
- Hepatic iron overload identified by magnetic resonance imaging-based T2* is a predictor of non-diagnostic elastography.Quantitative imaging in medicine and surgery · 2019Article
- Thalassemia and hepatocellular carcinoma: links and risks.Journal of blood medicine · 2019Article
- Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis.International journal of molecular sciences · 2018Review
- Liver Iron Concentration and Liver Impairment in Relation to Serum IGF-1 Levels in Thalassaemia Major Patients: A Retrospective Study.Mediterranean journal of hematology and infectious diseases · 2015Article
- Hepatocellular Carcinoma and Liver Transplantation: State of the Art.Journal of clinical and translational hepatology · 2014Review
- Use of magnetic resonance imaging to monitor iron overload.Hematology/oncology clinics of North America · 2014Review
- Role of iron in hepatocellular carcinoma.Clinical liver disease · 2014Article
- Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia.BioMed research international · 2014Review
- Secondary haemochromatosis in a patient with thalassemia intermedia.Current health sciences journal · 2014Article
- Management of hepatocellular carcinoma: Enlightening the gray zones.World journal of hepatology · 2013Article
- Pathophysiology and Clinical Manifestations of the β-Thalassemias.Cold Spring Harbor perspectives in medicine · 2012Article
- β-thalassemia intermedia: a clinical perspective.Cold Spring Harbor perspectives in medicine · 2012Review
- Hepatitis C virus infection in thalassemic patients with and without insulin dependent diabetes.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to blood transfusions, thalassemics are often infected with either hepatitis C virus (HCV) or hepatitis B virus and often have hemochromatosis. Hepatocellular carcinoma (HCC) has emerged in thalassemics only recently as a result of the improvement in thalassemia outcomes. In fact, a prospective study estimated an HCC incidence in β-thalassemia of about 2%. Although data are scanty, HCC screening in thalassemics with risk factors for HCC should be carried out. HCV treatments have some efficacy in HCV infected thalassemics despite partial contraindication to ribavirin and iron overload. However, there are no data on how HCV treatment translates into HCC prevention. Preliminary data suggest that HCC treatment in thalassemics should generally have the same outcomes as in non-thalassemics. Although coexistence of severe comorbidities makes liver transplantation challenging, this therapeutic possibility should not be precluded for well selected HCC β-thalassemia patients. In fact, 2 transfusion dependent adult HCC β-thalassemia patients have recently undergone successful liver transplantation with a good outcome. In conclusion, HCC seems to be a developing issue in thalassemia and HCC screening should be carried out. HCC treatment, including liver transplantation, can be performed in selected patients. A multidisciplinary effort is needed for management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.